Matthijs Versteegh 4/13/26 Matthijs Versteegh 4/13/26

The Cost Utility of Rhythm Control Treatment Sequences in Patients with Atrial Fibrillation: Anti-arrhythmic Drugs Versus Catheter Ablation

Matthijs Versteegh 4/13/26 Matthijs Versteegh 4/13/26

Consensus on evidence gaps and unmet needs in childhood myopia: findings from a European Delphi study with eye care professionals and payers

Matthijs Versteegh 4/13/26 Matthijs Versteegh 4/13/26

Antiarrhythmic drugs versus catheter ablation as rhythm control for atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials

Matthijs Versteegh 4/13/26 Matthijs Versteegh 4/13/26

Cost-effectiveness of treatment sequences following first-line rituximab in relapsing-remitting multiple sclerosis: a Norwegian microsimulation study

Matthijs Versteegh 8/26/25 Matthijs Versteegh 8/26/25

Cost–Utility Analysis of Treatment Sequences for Moderate-to-Severe Crohn’s Disease

Matthijs Versteegh 8/26/25 Matthijs Versteegh 8/26/25

Comparative efficacy of all available pharmaceutical therapies for moderate to severe Crohn’s disease: a systematic review and network meta-analysis

Matthijs Versteegh 7/28/25 Matthijs Versteegh 7/28/25

Exit strategies in patients with stable MS: Cost-effectiveness of extended interval dosing of ocrelizumab and natalizumab versus de-escalating to cladribine

Matthijs Versteegh 5/28/25 Matthijs Versteegh 5/28/25

Treatment-related toxicity, utility and patient-reported outcomes of head and neck cancer patients treated with proton therapy: A longitudinal study

Matthijs Versteegh 6/25/24 Matthijs Versteegh 6/25/24

Benefits of early highly effective versus escalation treatment strategies in relapsing multiple sclerosis estimated using a treatment-sequence model

$Effectiveness of Seizure Dogs for People With Severe Refractory Epilepsy Results From the EPISODE Study$

Matthijs Versteegh 3/25/24 Matthijs Versteegh 3/25/24

Effectiveness of Seizure Dogs for People With Severe Refractory Epilepsy Results From the EPISODE Study

Matthijs Versteegh 10/30/23 Matthijs Versteegh 10/30/23

Cost–effectiveness of alternative NTRK testing strategies in cancer patients followed by histology-independent therapy with entrectinib: an analysis of three European countries

Matthijs Versteegh 10/30/23 Matthijs Versteegh 10/30/23

Benefits of sphingosine-1-phosphate receptor modulators in relapsing MS estimated with a treatment sequence model

Matthijs Versteegh 10/3/23 Matthijs Versteegh 10/3/23

HEcoPerMed, personalized medicine from a health economic perspective: lessons learned and potential opportunities ahead

Matthijs Versteegh 8/14/23 Matthijs Versteegh 8/14/23

Budget impact and transferability of cost–effectiveness of DPYD testing in metastatic breast cancer in three health systems

Matthijs Versteegh 8/8/23 Matthijs Versteegh 8/8/23

Health-economic benefits of anti-CD20 treatments in relapsing multiple sclerosis estimated using a treatment-sequence model

Matthijs Versteegh 7/25/23 Matthijs Versteegh 7/25/23

Societal Utilities for Cognitive Impairment in Schizophrenia: Developing a Preference-Based Scoring Algorithm Based on the Schizophrenia Cognition Rating Scale

Matthijs Versteegh 4/19/23 Matthijs Versteegh 4/19/23

The value of health in a cost-effectiveness analysis: theory vs practice

Matthijs Versteegh 2/22/23 Matthijs Versteegh 2/22/23

The economics of patents and innovation in pharma

Matthijs Versteegh 10/11/22 Matthijs Versteegh 10/11/22

Cost-Effectiveness Analysis of Treating Patients With NTRK-Positive Cancer With the Histology-Independent Therapy Entrectinib

Matthijs Versteegh 8/4/22 Matthijs Versteegh 8/4/22

Future medical and non-medical costs and their impact on the cost-effectiveness of life-prolonging interventions: a comparison of five European countries

Publications.